SCHEMBL3910283

SCHEMBL3910283

O=C(Nc1ccc(Cl)cc1)c1ccncc1NC(=O)c1ccc(N2CCCC2)cc1OC1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ATM Q13315 1/20 0.48
IRAK4 Q9NWZ3 2/20 0.46
ATR Q13535 1/20 0.45
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
IRAK1 P51617 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
CLK2 P49760 2/20 0.42
CLK3 P49761 2/20 0.42
DYRK1A Q13627 2/20 0.42
PIM1 P11309 2/20 0.42
PIM3 Q86V86 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
FLT3 P36888 3/20 0.41
CDK2 P24941 1/20 0.41
CDK6 Q00534 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903409 0.91 F10 (0.48) IRAK4ATRIRAK1
Trifluoroacetic Acid SCHEMBL3898752 0.87 F10 (0.44) IRAK4ATRIRAK1PIM1PIM3
SCHEMBL3901505 0.86 MAPT (0.48) MEN1KMT2AATMPDE4APDE4B
SCHEMBL8287160 0.84 PTGDR (0.42) MEN1KMT2AIRAK4ATRPDE4A
SCHEMBL8286962 0.83 ATR (0.39) IRAK4ATRPDE4APDE4BPDE4C
SCHEMBL8285039 0.82 GRM5 (0.43) IRAK4PDE4APDE4BPDE4CPDE4D
SCHEMBL3157157 0.81 F10 (0.58)
SCHEMBL3151362 0.81 F10 (0.53) IRAK4
SCHEMBL5785047 0.81 IRAK4 (0.51) IRAK4IRAK1
SCHEMBL3170852 0.81 F10 (0.52) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511066-B2 Antithrombotic aromatic ethers ELI LILLY AND COMPANY (US) 2009-03-31 US disclosed
US-7511066-B2 Antithrombotic aromatic ethers ELI LILLY AND COMPANY (US) 2009-03-31 US disclosed
US-7511066-B2 Antithrombotic aromatic ethers ELI LILLY AND COMPANY (US) 2009-03-31 US disclosed
US-20070027185-A1 Antithrombotic aromatic ethers ELILILLY AND COMPANY (US) 2007-02-01 US disclosed
US-20070027185-A1 Antithrombotic aromatic ethers ELILILLY AND COMPANY (US) 2007-02-01 US disclosed
US-20070027185-A1 Antithrombotic aromatic ethers ELILILLY AND COMPANY (US) 2007-02-01 US disclosed
EP-1670783-A2 ANTITHROMBOTIC AROMATIC ETHERS ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005049604-A2 ANTITHROMBOTIC AROMATIC ETHERS ELI LILLY AND COMPANY (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027185-A1 Antithrombotic aromatic ethers F2, F11, TFPI MEN1 1746/4885KMT2A 2989/4885ATM 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.